Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received March 4, 2019
- Revision received September 11, 2019
- Accepted October 11, 2019
- Published first October 22, 2019.
Article Versions
- You are currently viewing a Previous version of this article (October 22, 2019 - 06:33).
- View the most recent version of this article
Copyright & Usage
Copyright ©2019, American Association for Cancer Research.
Author Information
- ↵* Corresponding Author:
Jeff Settleman, Oncology R&D, Pfizer (United States), San Diego, CA, 92121, United States. E-mail: jeffrey.settleman{at}pfizer.com
Published OnlineFirst October 22, 2019
doi: 10.1158/0008-5472.CAN-19-0729
A single-step, high-dose selection scheme reveals distinct mechanisms of acquired resistance to oncogenic kinase inhibition in cancer cells
Jump to section
Advertisement